NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

Now Viewing

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

Video content above is prompted by the following question(s):

• Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?

Related Videos

Related Content

Advertisement

January 7th 2025

Decisions and Precision in Value-Based Cancer Care

Hayden E. Klein

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

December 26th 2024

ICYMI: Highlights From AMCP Nexus 2024

Kyle Munz

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

December 25th 2024

Top 5 Most-Read Oncology Content of 2024

Pearl Steinzor

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Related Content

Advertisement

January 7th 2025

Decisions and Precision in Value-Based Cancer Care

Hayden E. Klein

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

December 26th 2024

ICYMI: Highlights From AMCP Nexus 2024

Kyle Munz

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

December 25th 2024

Top 5 Most-Read Oncology Content of 2024

Pearl Steinzor

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!